The US Food and Drug Administration has awarded trastuzumab deruxtecan rapid approval in advanced or unresectable HER2-positive BC that has been treated with at least two HER2-targeting therapy lines, based on results from recent clinical studies. Here, ERBB2 is linked to breast cancer.